IBDEI0XT ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16692,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,16692,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,16693,0)
 ;;=288.09^^92^940^8
 ;;^UTILITY(U,$J,358.3,16693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16693,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,16693,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,16693,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,16694,0)
 ;;=V10.21^^92^940^61
 ;;^UTILITY(U,$J,358.3,16694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16694,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,16694,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,16694,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,16695,0)
 ;;=284.2^^92^940^106
 ;;^UTILITY(U,$J,358.3,16695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16695,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,16695,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,16695,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,16696,0)
 ;;=202.40^^92^940^76
 ;;^UTILITY(U,$J,358.3,16696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16696,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,16696,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,16696,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,16697,0)
 ;;=287.49^^92^940^118
 ;;^UTILITY(U,$J,358.3,16697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16697,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,16697,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,16697,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,16698,0)
 ;;=180.9^^92^940^29
 ;;^UTILITY(U,$J,358.3,16698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16698,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,16698,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,16698,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,16699,0)
 ;;=203.02^^92^940^104
 ;;^UTILITY(U,$J,358.3,16699,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16699,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,16699,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,16699,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,16700,0)
 ;;=204.02^^92^940^2
 ;;^UTILITY(U,$J,358.3,16700,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16700,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,16700,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,16700,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,16701,0)
 ;;=204.12^^92^940^17
 ;;^UTILITY(U,$J,358.3,16701,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16701,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,16701,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,16701,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,16702,0)
 ;;=204.20^^92^940^114
 ;;^UTILITY(U,$J,358.3,16702,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16702,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,16702,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,16702,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,16703,0)
 ;;=204.21^^92^940^116
 ;;^UTILITY(U,$J,358.3,16703,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16703,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,16703,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,16703,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,16704,0)
 ;;=204.22^^92^940^115
 ;;^UTILITY(U,$J,358.3,16704,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16704,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,16704,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,16704,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,16705,0)
 ;;=205.02^^92^940^5
 ;;^UTILITY(U,$J,358.3,16705,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16705,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,16705,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,16705,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,16706,0)
 ;;=205.12^^92^940^20
